Could a bile acid and herbal mix treat Diabetes-Related vision loss?
NCT ID NCT07457632
First seen Jun 27, 2026 · Last updated Jul 14, 2026 · Updated 2 times
Summary
This study tests whether two dietary supplements—tauroursodeoxycholate (a bile acid) and a traditional Chinese medicine formula—can help people with diabetic macular edema, a vision-threatening complication of diabetes. The 69 participants will take the supplements or a placebo for several months. The goal is to see if this approach reduces eye inflammation and improves vision by targeting liver health, which may play a role in the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Tauroursodeoxycholate (TUDCA) and a traditional Chinese medicine formula (modified Qi Ju Di Huang Wan)
- What this could lead to
- If it works, this could offer a non-invasive, multi-targeted treatment option for diabetic macular edema that addresses underlying inflammation rather than just local eye problems.
- What could go wrong
- This is an early phase 2 trial with only 69 participants, so results may not apply to everyone. The supplements may not improve vision or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETIC MACULAR EDEMA (DME) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Alabama at Birmingham
Birmingham, Alabama, 35243, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new eye injection beat the current standard for diabetic vision loss?
- AI could predict which eye treatments work best for Diabetes-Related vision loss
- New eye drug EYE103 takes on lucentis in major trial for Diabetes-Related vision loss
- New dosing strategy could mean fewer eye injections for Diabetes-Related vision loss
- New syringe could simplify High-Dose eye treatment
- Eye scan showdown: faricimab vs ranibizumab in diabetic retinopathy